Advertisement

Antiviral Properties of the New Coordination Compound Silver Bis(Citrato)Germanate

  • I. I. Seifullina
  • E. É. Martsinko
  • T. L. GridinaEmail author
  • E. A. Chebanenko
  • L. M. Mudrik
  • A. S. Fedchuk
Article
  • 1 Downloads

The new coordination polymer silver bis(citrato)germanate was synthesized and exhibited pronounced antiviral activity against human influenza virus strains A/Hong Kong/1/68 (H3N2) and A/Puerto Rico/34 (H1N1). Its effective dose was five times lower than that of the reference drug oseltamivir, which made this compound promising for further studies in animal models.

Keywords

silver bis(citrato)germanate coordination compounds anti-influenza activity human influenza viruses 

References

  1. 1.
    N. A. Shkil’, V. A. Burmistrov, and M. Yu. Sokolov, Nauchn. Zh. KubGAU, 68(04), (2011).Google Scholar
  2. 2.
    I. S. Chezhman, Nauka Innovatsii, 11(1), 72 – 77 (2015); doi: http: // dx.doi.org / 10.15407 / scin11.01.072.Google Scholar
  3. 3.
    L. G. Menchikov and M. A. Ignatenko, Khim.-farm. Zh., 46(11), 3 – 6 (2012); Pharm. Chem. J., 46(11), 635 – 638 (2013).Google Scholar
  4. 4.
    WHO Guidelines for Pharmacological Management of Pandemic (H1N1) 2009 Influenza and Other Influenza Viruses; http: // www.who.int / csr / resources / publications / swineflu / h1n1 use antivirals 20090820 / en / index.htmlGoogle Scholar
  5. 5.
    T. L. Gridina, Odess. Med. Zh., 151(5), 76 – 80 (2015).Google Scholar
  6. 6.
    L. V. Gubareva and F. G. Hayden, Influenza Virology: Current Topics, Caister Press,Wymondham, U. K., 2006, pp. 169 – 202.Google Scholar
  7. 7.
    Center of Diesis Control and Prevention. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis, MMWR Morb. Mortal. Wkly. Rep., 58, 969 – 972 (2009).Google Scholar
  8. 8.
    T. A. Mikhas’ko, B. V. Dubovik, O. I. Shadyro, et al., Med. Nov., 4, 81 (2012).Google Scholar
  9. 9.
    I. Seifullina, E. Martsinko, E. Chebanenko, et al., Program and Abstracts of the 29 th International Conference on Antiviral Research, La Jolla, 2016, Abstr. 165; http: // c.ymcdn.com / sites / www.isar-icar.com / resource / resmgr / ISAR_Program2016_webApril11.pdf [https: // www.isar-icar.com / resources / Documents / ISAR Program2016 webApril11.pdf]Google Scholar
  10. 10.
    V. S. Sergienko, E. E. Martsinko, I. I. Seifullina, et al., Crystallogr. Rep., 61(2), 203 – 208 (2016).CrossRefGoogle Scholar
  11. 11.
    A. V. Stefanov (ed.), Preclinical Drug Trials, Methodical Recommendations [in Russian], Avitsenna, Kiev, 2002.Google Scholar
  12. 12.
    B. W. J. Mahy (ed.), Virology, IRL Press, Oxford, 1985.Google Scholar
  13. 13.
    I. P. Ashmarin, Zh. Mikrobiol., No. 2, 102 – 108 (1959).Google Scholar
  14. 14.
    E. V. Gubler and A. A. Genkin, Application of Nonparametric Criteria of Statistics to Medical and Biological Studies [in Russian], Meditsina, Leningrad, 1973.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • I. I. Seifullina
    • 1
  • E. É. Martsinko
    • 1
  • T. L. Gridina
    • 2
    Email author
  • E. A. Chebanenko
    • 1
  • L. M. Mudrik
    • 3
  • A. S. Fedchuk
    • 3
  1. 1.I. I. Mechnikov Odessa National UniversityOdessaUkraine
  2. 2.Odessa National Medical UniversityOdessaUkraine
  3. 3.Odessa Research Center Biomedical Testing of Food and DrugsOdessaUkraine

Personalised recommendations